Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Safety of opioid patch initiation in Australian residential aged care

- Featured Image

Opioid analgesics are recommended for the treatment of cancer pain and for short-term treatment of moderate to severe acute pain.1,2 The number of opioid prescriptions in Australia reimbursed by the Pharmaceutical Benefits Scheme increased from 2.4 million in 2002 to 7.0 million in 2007.3 Much of this increase is probably driven by the increased administration of opioids for chronic non-cancer pain,3,4 but such use remains controversial, especially in older people, as they are more susceptible to adverse drug events.57

Transdermal opioid patches have been designed to provide long-lasting therapy for patients with chronic pain. Two opioids are available for administration via transdermal patches: fentanyl and buprenorphine. Fentanyl patches have a duration of action of 3 days, while buprenorphine patches are active for 7 days.1 In addition to an extended duration of action, transdermal opioids also have a slower onset of action, making them unsuitable for the management of acute pain.1

For chronic, non-cancer pain, Australian guidelines recommend a stepwise approach,…